Cargando…
Combined sodium glucose co‐transporter‐2 inhibitor and angiotensin‐converting enzyme inhibition upregulates the renin‐angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double‐blind, placebo‐controlled exploratory trial
AIM: Sodium glucose co‐transporter‐2 inhibitors (SGLT‐2i) improve cardiorenal outcomes in patients with chronic kidney disease (CKD), with and without type 2 diabetes. The molecular mechanisms underlying these pleiotropic effects remain unclear, yet it is speculated that SGLT‐2i elicit a neurohormon...
Autores principales: | Antlanger, Marlies, Domenig, Oliver, Kaltenecker, Christopher C., Kovarik, Johannes J., Rathkolb, Vincent, Müller, Martin M., Schwaiger, Elisabeth, Hecking, Manfred, Poglitsch, Marko, Säemann, Marcus D., Kopecky, Chantal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305250/ https://www.ncbi.nlm.nih.gov/pubmed/34984822 http://dx.doi.org/10.1111/dom.14639 |
Ejemplares similares
-
Molecular remodeling of the renin-angiotensin system after kidney transplantation
por: Antlanger, Marlies, et al.
Publicado: (2017) -
Effect of Mineralocorticoid Receptor Antagonism and ACE Inhibition on Angiotensin Profiles in Diabetic Kidney Disease: An Exploratory Study
por: Kovarik, Johannes J., et al.
Publicado: (2021) -
Intrarenal Renin-Angiotensin-System Dysregulation after Kidney Transplantation
por: Kovarik, Johannes J., et al.
Publicado: (2019) -
Neprilysin is a Mediator of Alternative Renin-Angiotensin-System Activation in the Murine and Human Kidney
por: Domenig, Oliver, et al.
Publicado: (2016) -
The systemic renin-angiotensin system in COVID-19
por: Reindl-Schwaighofer, Roman, et al.
Publicado: (2022)